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Objectives. To study adherence to methotrexate (MTX) and factors of importance thereof in patients with rheumatoid arthritis
(RA). Methods. Patients with a hospital diagnosis of RA (ICD10 codes M05.X or M06.X) after January 1, 1997, and aged ≥18 years
at the date of first diagnosis/contact, with at least one prescription of MTX (L04AX03), were included. Results. A total of 18,703
(47.6%) patients had ever used MTX among 39,286 with a diagnosis of RA; among the MTX users, 16,503 (88.2%) had filed more
than one MTX prescription. The median time from diagnosis to first MTX prescription was 0.66 (IQR 0.26–1.80) years. In those
who filed more than one MTX prescription, the mean adherence time for ≥7.5mg MTX per week was 1,925 (IQR 467–3,056) days
for patients treated in private practice versus 1,892 (IQR 452–3,316) days for patients treated in hospital. The main determinants of
nonadherence were female gender, younger age, and time from diagnosis to initiation of MTX. Conclusions. Treatment at hospital
or in private practice did not influence the adherence to MTX. Nonmodifiable factors of importance were gender and age, while
adherence to MTX therapy decreased with time lapse between diagnosis and prescription.
1. Introduction
The diagnosis “rheumatoid arthritis” (RA) is based on a
pattern of symptoms and physical examination findings,
with and often without any radiographic or serologic abnor-
malities [1, 2]. To avoid joint damage, inflammation in
patients with RA should be suppressed as much as possible
[3]. According to the treat-to-target paradigm, the primary
goal of treating the RA patient is to maximise long-term
health-related quality of life through control of symptoms,
prevention of structural damage, normalisation of function,
and social participation [4, 5]. Methotrexate (MTX) is the
appropriate first-line agent for most patients with RA [5];
MTX is the “anchor drug” for treatment of RA.This is due to
a combination of effectiveness and a favourable safety profile
compared to other disease-modifying antirheumatic drugs
(DMARDs) [5, 6].
Real-life registry data indicate that patients to a larger
extent remain on antirheumatic biologic agentswhen given in
combination with MTX [7]. However, preliminary Canadian
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healthcare data indicate that when MTX is prescribed in
conjunction with a biologic agent, more than half of the
patients do not collect their MTX prescription [8, 9]. If
these estimates are justified, the clinical practice guidelines
could be in conflict with the item accepted unanimously by
the “treat-to-target” task force stating that “the treatment of
RA must be based on a shared decision between patient and
rheumatologist” [4]. Adherence to MTX may fluctuate; that
is, patients do no quit their medication fully but possibly
taper the intake over time. Based on this assumption, the
current study used a definition of adherence with cut-offs
corresponding to use of MTX at or above 7.5mg (3 tablets of
2.5mg) per week, respectively, 5mg per week.
The objective of this population based cohort studywas to
explore the adherence to MTX use in the Danish population
in subjects with a hospital registered diagnosis of rheumatoid
arthritis.
2. Methods
2.1. Study Design. The study was designed as a cohort study
with patients with a hospital diagnosis of arthritis (ICD10
codes M05.X, M06.X). The cohort was constructed using
data from (1) the National Hospital Discharge Register
(Landspatientregisteret—an ICD10 diagnosis of M05.X or
M06.X) and (2) the National Prescription Register (Lægem-
iddeldatabasen—at least one prescription of MTX) for the
period January 1, 1997, until December 31, 2012 (both dates
included). In order to exclude prevalent cases, only subjects
diagnosed after January 1, 1998, and aged ≥18 years at the
date of first diagnosis/contact and who had filed at least
one prescription for MTX (ATC L04AX03) were considered.
The index date was the date of first MTX prescription on
or after January 1, 1998 (and after the first ICD10 M05X
or M06X diagnosis). The cohort was constructed from the
Danish population of approximately 5.4 million inhabitants.
The patients were followed until death, migration, December
31, 2012, or any specified endpoint.
2.2. Registers Used. The information on occurrence of speci-
fied diseases is registered in the National Hospital Discharge
Register founded in 1977 [10]. It covers all inpatient contacts
from 1977 to 1994 and from 1995 also all outpatient visits
to hospitals, outpatient clinics, and emergency rooms. Upon
discharge, the physician codes the contact diagnosis using
the ICD system. The code used is at the discretion of the
individual physician. The register has a nationwide coverage
and an almost 100%capture of contacts. In general the validity
of registrations is high [11].
The Danish Medicines Agency keeps a nationwide reg-
ister of all drugs sold at pharmacies throughout the coun-
try from 1996 and onwards (The National Pharmaco-
logical Database run by the Danish Medicines Agency:
http://www.dkma.dk). Any drugs bought are registered with
an ATC code, dosage sold, form of administration (tablets,
injections, etc.), and date of sale. Information on patient
contacts to practising specialists (here rheumatologists) was
obtained from the National Register on contacts to general
practitioners or specialists (Sygesikringsregistret). This reg-
ister is used to reimburse, for example, specialists based on
the consultations or treatments performed. Information on
vital status and migrations was extracted from the National
Person Register. All subjects are followed up until time of
death, migration, any defined event, or December 31, 2012,
whichever came first.
The present study linked these sources of information
through the Central Person Register Number which is a
unique registration code given to every inhabitant—to some
degree similar to the American social security number—that
allows registration on an individual basis but under code for
the researchers who had no specific access to individualized
data. The project was approved by the National Board of
Health and the Danish Data Protection Agency.
2.3. Outcomes and Potential Endpoint Predictors. It was
hypothesised that MTX adherence is better in RA patients
treated by private practising rheumatologists compared to
RA patients treated in hospital outpatient clinics and MTX
adherence diminishes over time with concomitant use of
prednisolone.
Outcomes. Cessation of MTX use is defined as (1) filed
prescriptions of less than 7.5mg MTX per week of
observation or (2) filed prescriptions of less than 5mg MTX
per week of observation. In this instance it should be noted
that 7.5mg MTX per week is the recommended minimal
dose to attain remission.
Exposure Variables. They are use of NSAIDs within the last
year prior to diagnosis, use of prednisone/prednisolone
within the last year prior to diagnosis, duration of RA
diagnosis before MTX prescription, and the fact of being
seen by a practising specialist in rheumatology in private
practice versus being managed in hospital.
Confounders/Effect Modifiers. They are age, gender, and
Charlson comorbidity index (except for connective tissue
disorders, which were covered by the inclusion criteria) [12].
The Charlson index was chosen as this is a generally accepted
register based evaluation of comorbidity.
2.4. Statistical Analysis. Mean and standard deviations (SD)
as well as frequencies were used as descriptive statistics.
Adherence to MTX was analysed using Kaplan-Meier sur-
vival functions. Analyses were performed using 𝑡-test for two
samples, 𝜒2-statistics, and Cox proportional hazard regres-
sion as appropriate. In the Cox regression the proportional
hazard assumption was tested using log-minus-log plots. A
significance level of 0.05 was chosen. SPSS20.0 (IBM Corp.)
and STATA12 (STATA Corp.) were used for the analyses.
3. Results
3.1. Participants. Figure 1 shows the sampling profile among
inhabitants in Denmark: from the 5.4 million eligible inhab-
itants, 4.1 million were aged 18 years or more, and of these
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5,368,354
4,191,428
39,286
18,703
16,503
Inhabitants in Denmark
ICD10 M05/06 after January 1, 1997 (100.0%)
Ever use of MTX after diagnosis (47.6%)
Use of 1 prescription of MTX after diagnosis (42.0%)
Inhabitants in Denmark
>
≥18 years
Figure 1: Study population (flow diagram). The study period began
January 1, 1997. However, to exclude prevalent cases, only those with
a de novo diagnosis after January 1, 1998, were included.
39,286 had had a diagnosis of RA, and among these a
little less than half of them (18,703; 47.6%) had ever filed a
prescription for MTX. Due to the extensive nature of the
registers, all could be followed until time of death, migration,
or December 31, 2012, whichever came first. Table 1 shows
the characteristics of the participants and information on
exposures and potential confounders. Comorbid conditions
were scarce—most numbering a few per cent.
3.2. Main Results. The patients were followed up for a total
of 146,012 years (mean: 7.8 ± 3.7 years, median 7.7 years).
Long-term follow-up was thus present in most patients. Out
of the 18,703, a total of 6,160 (32.9%) took less than 5mg of
MTX per week of follow-up, while 8,131 (43.5%) took less
than 7.5mg of MTX per week of follow-up. By consequence,
many RA patients took less than the lowest recommended
dose of MTX. The median time from diagnosis to first MTX
prescriptionwas 0.66 (IQR0.26–1.80) years. Post hoc division
of the material showed a time lapse of 0.59 (IQR 0.24–1.18)
years in the period 1998–2004 and 0.92 (0.31–4.41) years in
the period 2005–2012 (Table 1).
Table 2 presents the crude determinants of receiving only
one or receiving two or more MTX prescriptions. In general
those with a comorbid condition were less likely to file more
than one prescription of MTX. However, in some cases the
differences were small in absolute terms (e.g., 85% versus 84%
for prior prednisolone use or not) although the difference
attained statistical significance due to the large number of
exposed subjects.
Figure 2 (including all prescriptions) and Figure 3 (only
considering those who filed two or moreMTX prescriptions)
show the Kaplan-Meier plots of adherence to MTX strati-
fied by whether they were seen by practising specialists in
rheumatology or not. No difference in adherence to MTX
was present between thosemanaged in private practice (1,925
(IQR 467–3,056) days) versus 1,892 (IQR 452–3,316) days for
patients treated in hospital. In those who filed more than one
MTX prescription, the mean adherence time for 7.5mgMTX
per week was 2,245 (IQR 986–3,407) days.
Table 3 shows the crude and adjusted hazard rates (HR) of
using less than 5mg of MTX per week or 7.5mg of MTX per
week, respectively. The adjustment in the Cox proportional
Days from first MTX prescription
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Figure 2: Adherence to MTX. Use of 7.5mg per week stratified by
whether the patient was seen by a practicing specialist or not. Days
from first prescription.
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Figure 3: Adherence to MTX. Use of 5mg per week stratified by
whether the patient was seen by a practicing specialist or not. Days
from first prescription.
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Table 1: Characteristics of RA patients at the time of first MTX
prescription.
Variables Number
Age (years ± SD) 59.8 ± 14.4
Men 5,221 (28%)
Women 13,482 (72%)
AMI 774 (4%)
Cerebrovascular disease 991 (5%)
Dementia 80 (0.4%)
Complications to T1D 183 (1%)
Complications to T2D 279 (2%)
T1DM 322 (2%)
T2DM 734 (4%)
Hemiplegia 30 (0.2%)
Heart failure 687 (4%)
Peripheral vascular disease 694 (4%)
Chronic lung disease 1,562 (8%)
Leukemia 29 (0.2%)
Lymphoma 99 (0.5%)
Metastases 98 (0.5%)
Mild liver disease 204 (1%)
Moderate to severe liver disease 29 (0.2%)
Kidney disease 328 (2%)
Cancer 476 (3%)
Ulcer 1,207 (7%)
NSAID within the last year 13,415 (72%)
Prednisolone/prednisone within the last
year 9,052 (48%)
Ever prior use of
prednisolone/prednisone 11,444 (61%)
Ever seen by private practicing
rheumatologist 4,497 (24%)
Time from diagnosis to first MTX
prescription (years) 0.66 (IQR 0.26–1.80)
T1DM: type 1 diabetes mellitus.
T2DM: type 2 diabetes mellitus.
hazard regression included all confounders shown. Adjust-
ment only changed the estimates little. In general female gen-
der, T2D with complications, COPD, atherosclerosis, mild
liver disease, and kidney disease all increased the likelihood
of nonadherence to both 5 and 7.5mg MTX per week in the
multiple adjusted analysis. Increasing age decreased the likeli-
hood of nonadherence (i.e., elderly weremore compliant with
MTX). Increasing time span between diagnosis and first pre-
scription of MTX increased the likelihood of nonadherence.
Being seen by a rheumatologist in private practice did not
differ from hospital follow-up in terms of adherence toMTX.
4. Discussion
The present study demonstrated that, after an initial loss
of adherence, the remainder Danish RA patients slowly but
steadily dropped out of treatment over the following years.
“Half-life” on MTX in patients with more than one prescrip-
tion was, however, over 4000 days, provided an acceptance
of 7.5mg MTX per week as compliant, corresponding to the
lower limit of recommended dose. These results are in some
contrast with the notion of a very low adherence to MTX,
while they add a time perspective to previous indications
[13] of the development of nonadherence [8, 9]. The even
better adherence to 5mg MTX per week seems to confirm
our hypothesis that patients taper their dosage of MTX to a
rather low level, while they do not fully withdraw from this
treatment.
The adherence toMTXwas associatedwith general health
as demonstrated by the significantly higher drop-out rate in
patients with comorbid conditions, while this development
may also reflect a modulation of the treating physician due to
comorbidities. Nevertheless, the elderly weremore compliant
withMTX than younger RApatients, which seems to confirm
our immediate expectations that in general the elderly do
what their treating physician tells them more often than
younger subjects.
Themain part of the participants, some 85%, had received
prednisolone for the RA, while interestingly use of pred-
nisolone at baseline did not influence the adherence to MTX
to any clinically significant extent. There was delay of more
than a half year on average from diagnosis to the first
prescription of MTX, which may reflect a Danish tradition
with prednisolone being used more than recommended by
current guidelines [5]. This diversion from standard may
potentially affect the adherence as demonstrated by the lower
retention rate with increasing time between diagnosis and
MTX prescription.
4.1. Limitations. Our study group was defined by a diagnosis
of RA from the hospital register. Thus, patients having never
been admitted to hospital and only having received treatment
in rheumatology practice were not included. However, we
found no difference in adherence between patients having
prescriptions of MTX at a hospital outpatients clinic as
compared to patients being followed up by a practising
rheumatologist. In a hospital setting, Danish RA patients are
subjected tomore frequent changes in treating physician than
in rheumatology practice, which in Denmark is run by only
one specialist. This observation also leads to a conclusion
that Danish RA patients comply with medication due to
tradition rather than personal contact with a specific doctor.
As a confounder to this statement, some patients may have
initiated their treatment in one or other of these institutions,
while continuing therapy in the opposite.
The present study assumed that the dataset from The
National Pharmacological Database reflected actual use of
MTX, while no interviews or other indications of actual
ingestion of MTX were obtained. The data, however, add to
the experiences from other countries, but in our case based
on robust prescription data from high quality Danish reg-
isters. A possible development toward earlier prescriptions
of MTX due to changes in guidelines may be expected in
the future, but not yet detectable in a retrospective cohort as
Arthritis 5
Table 2: Characteristics of patients filing only one or filing more than one MTX prescription: predictors of filing only one or filing two or
more MTX prescriptions.
Variables One MTX prescription Two or more MTXprescriptions
𝑃 value (Pearson
chi-square test, 2-sided)
≤50 years 679 (15%) 3,849 (85%)
<0.00151–60 years 648 (15%) 3,672 (85%)
61–70 years 631 (13%) 4,223 (87%)
>70 years 950 (19%) 4,053 (81%)
Men 784 (15%) 4,447 (85%) 0.089
Women 2,161 (16%) 11,350 (84%)
No prior use of prednisolone/prednisone 1,053 (15%) 6,206 (85%) 0.002
Prior use of prednisolone/prednisone 1,853 (16%) 9,591 (84%)
No AMI 2,741 (15%) 15,188 (85%)
<0.001
AMI 165 (21%) 609 (79%)
No cerebrovascular disease 2,697 (15%) 15,015 (85%)
<0.001
Cerebrovascular disease 209 (21%) 782 (79%)
No dementia 2,884 (15%) 15,739 (85%) 0.003
Dementia 22 (27%) 58 (73%)
No complications to T1D 2,860 (15%) 15,660 (85%)
<0.001
Complications to T1D 46 (25%) 137 (75%)
No complications to T2D 2,834 (15%) 15,590 (85%)
<0.001
Complications to T2D 72 (26%) 207 (74%)
No T1D 2,830 (15%) 15,551 (85%)
<0.001
T1D 76 (24%) 246 (76%)
No T2D 2,751 (15%) 15,218 (85%)
<0.001
T2D 155 (21%) 579 (79%)
No hemiplegia 2,898 (15%) 15,775 (85%) 0.092
Hemiplegia 8 (27%) 22 (73%)
No heart failure 2,735 (15%) 15,281 (85%)
<0.001
Heart failure 171 (25%) 516 (75%)
No peripheral vascular disease 2,741 (15%) 15,268 (85%)
<0.001
Peripheral vascular disease 165 (24%) 529 (76%)
No chronic lung disease 2,553 (15%) 14,588 (85%)
<0.001
Chronic lung disease 353 (23%) 1,209 (77%)
No leukemia 2,901 (15%) 15,773 (85%) 0.800
Leukemia 5 (17%) 24 (83%)
No lymphoma 2,886 (15%) 15,718 (85%) 0.199
Lymphoma 20 (20%) 79 (80%)
No metastases 2,880 (15%) 15,725 (85%) 0.003
Metastases 26 (26%) 72 (74%)
No mild liver disease 2,852 (15%) 15,647 (85%)
<0.001
Mild liver disease 54 (26%) 150 (74%)
No moderate to severe liver disease 2,903 (15%) 15,771 (85%) 0.440
Moderate to severe liver disease 3 (10%) 26 (90%)
No kidney disease 2,816 (15%) 15,560 (85%)
<0.001
Kidney disease 90 (27%) 237 (73%)
No cancer 2,813 (15%) 15,414 (85%) 0.015
Cancer 93 (19%) 383 (81%)
No ulcer 2,664 (15%) 14,832 (85%)
<0.001
Ulcer 242 (20%) 965 (80%)
in the present study. Unfortunately, registration of biological
medications is not given in the national,mandatory databases
used in the study, and thus no data of a possible influence of
such medication on MTX use were available.
Associations between adherence to MTX and clinical
impact on disease activity could not be detected in the official
databases and no systematic registration is available of, for
example, disease activity scores including joint evaluations.
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Table 3: Risk of nonadherence toMTX: Cox proportional hazard model; crude andmultiply adjusted hazard rates (HR) and 95% confidence
intervals (CI).
Variables at baseline 5mg per week 7.5mg per week 5mg per week
# 7.5mg per week#
Crude OR (95% CI) Crude OR (95% CI) HR (95% CI) HR (95% CI)
Gender (F/M) 1.21 (1.13–1.30)∗ 1.18 (1.11–1.26)∗ 1.12 (1.06–1.19)∗ 1.07 (1.01–1.12)∗
NSAID within last year 1.09 (1.01–1.16)∗ 1.08 (1.01–1.15)∗ 1.03 (0.97–1.09) 1.01 (0.96–1.06)
Prednisolone within last year 0.91 (0.86–0.97)∗ 0.93 (0.88–0.98)∗ 0.99 (0.94–1.04) 1.00 (0.96–1.04)
Biological antirheumatic therapy 0.74 (0.24–2.32) 1.48 (0.54–4.07) 0.65 (0.24–1.73) 1.04 (0.52–2.09)
AMI 0.90 (0.77–1.05) 0.85 (0.73–0.98)∗ 1.07 (0.93–1.22) 1.01 (0.90–1.14)
Cerebrovascular events 0.94 (0.82–1.08) 0.95 (0.84–1.09) 1.11 (0.99–1.25) 1.14 (1.03–1.26)∗
Dementia 0.77 (0.47–1.26) 1.01 (0.65–1.57) 1.14 (0.75–1.74) 1.46 (1.05–2.02)∗
T1D with complications 1.07 (0.79–1.45) 1.01 (0.75–1.35) 0.97 (0.71–1.33) 0.92 (0.69–1.21)
T2D with complications 1.29 (1.01–1.65)∗ 1.26 (0.99–1.59) 1.34 (1.07–1.68)∗ 1.30 (1.06–1.58)∗
T1D 1.06 (0.84–1.33) 1.05 (0.84–1.31) 0.93 (0.72–1.19) 0.96 (0.78–1.19)
T2D 1.05 (0.90–1.23) 1.08 (0.93–1.25) 1.06 (0.91–1.24) 1.10 (0.96–1.25)
Hemiplegia 1.36 (0.66–2.81) 1.14 (0.56–2.33) 1.45 (0.82–2.57) 1.33 (0.78–2.24)
Heart failure 0.91 (0.77–1.08) 0.94 (0.81–1.10) 1.12 (0.97–1.29) 1.20 (1.06–1.36)∗
Atherosclerosis 0.93 (0.79–1.09) 1.01 (0.86–1.17) 1.12 (0.97–1.28) 1.23 (1.10–1.39)∗
COPD 1.10 (0.98–1.22) 1.03 (0.93–1.14) 1.23 (1.12–1.35)∗ 1.21 (1.11–1.31)∗
Leukemia 0.65 (0.28–1.51) 1.06 (0.51–2.20) 0.85 (0.41–1.79) 1.37 (0.80–2.37)
Lymphoma 0.93 (0.61–1.42) 0.96 (0.64–1.43) 1.03 (0.72–1.47) 1.05 (0.77–1.42)
Metastatic malignancy 0.62 (0.39–0.99)∗ 0.60 (0.39–0.92)∗ 0.85 (0.57–1.29) 0.90 (0.63–1.28)
Mild liver disease 1.35 (1.02–1.78)∗ 1.25 (0.95–1.65) 1.30 (1.05–1.63)∗ 1.28 (1.05–1.56)∗
Moderate liver disease 0.65 (0.28–1.51) 0.68 (0.32–1.46) 0.70 (0.33–1.47) 0.76 (0.41–1.42)
Kidney disease 1.39 (1.11–1.73)∗ 1.30 (1.04–1.61)∗ 1.35 (1.14–1.61)∗ 1.31 (1.12–1.53)∗
Solid cancer 0.91 (0.75–1.11) 0.85 (0.71–1.03) 1.05 (0.89–1.24) 1.00 (0.86–1.16)
Ulcer disease 0.94 (0.83–1.06) 0.96 (0.85–1.07) 1.07 (0.96–1.18) 1.08 (0.98–1.18)
Age
<50 years 1 (reference) 1 (reference) 1 (reference) 1 (reference)
50–59 years 0.79 (0.72–0.86)∗ 0.76 (0.70–0.82)∗ 0.84 (0.79–0.90)∗ 0.83 (0.78–0.88)∗
60–69 years 0.59 (0.55–0.65)∗ 0.58 (0.53–0.63)∗ 0.70 (0.66–0.76)∗ 0.73 (0.69–0.78)∗
≥70 years 0.59 (0.54–0.64)∗ 0.61 (0.56–0.66)∗ 0.77 (0.72–0.83)∗ 0.89 (0.83–0.95)∗
Private practising rheumatologist 0.95 (0.89–1.03) 0.99 (0.92–1.06) 0.97 (0.92–1.03) 1.02 (0.97–1.07)
Difference from diagnosis to MTX
<0.5 years 1 (reference) 1 (reference) 1 (reference) 1 (reference)
0.5–0.99 years 0.69 (0.64–0.75)∗ 0.74 (0.69–0.80)∗ 0.74 (0.69–0.79)∗ 0.80 (0.76–0.85)∗
≥1 year 1.07 (1.00–1.15) 1.02 (0.96–1.09) 1.17 (1.11–1.24)∗ 1.21 (1.15–1.27)∗
F: female; M: male; AIDS: acquired immune-deficiency syndrome; AMI: acute myocardial infarction; T1D: type 1 diabetes; COPD: chronic obstructive
pulmonary disease.
#Mutually adjusted for the other variables in the table (Cox proportional hazard regression).
∗
𝑃 < 0.05.
4.2. Perspectives. The present data suggest that, in Denmark,
only about half of the RApatients are given the recommended
first-line treatment with MTX. Also, on average the first
prescription ofMTX is delayed for more than half a year after
the diagnosis of RA. The possible consequences would seem
to be a risk of erosions developing during this lag-phase.With
notion of effective and targeted therapy, especially with usage
of MTX [6, 7], this local tradition would need to be changed.
5. Conclusions
DanishRApatients receiveMTX for their disease only in little
less than half of the cases. This result is the same whether
treatment is monitored by a hospital clinic or practicing
rheumatologist. Once on MTX, the majority of patients
adhere for many years to the treatment but taper the dosage
to rather low levels. Adherence to MTX therapy decreases
with time lapse between diagnosis and prescription. All
these results suggest that a more meticulous instruction and
campaign towards early TMX use is relevant among both
rheumatologists and patients.
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